PT-141
Bremelanotide (Vyleesi)
Mechanism of Action
Melanocortin 3/4 receptor (MC3R/MC4R) agonist. Acts centrally on hypothalamic and mesolimbic circuits involved in sexual arousal, rather than on penile/vascular smooth muscle like PDE5 inhibitors — explaining its efficacy independent of vascular blood flow.
Key Benefits
- FDA-approved efficacy for HSDD in premenopausal women (RECONNECT phase 3 trials)
- On-demand dosing rather than daily use
- Effective independent of vascular mechanism — an option when PDE5 inhibitors underperform
- Off-label male use for libido/arousal support is common in research/TRT-adjacent practice, though not FDA-studied in men
Dosing Protocol
Nausea is the dose-limiting side effect; many protocols start at 1 mg before moving to the FDA-labeled 1.75 mg dose. FDA data covers only premenopausal women — male dosing is extrapolated off-label.
Ideal Candidates
FDA-approved population: premenopausal women with acquired generalized HSDD. Off-label: men seeking libido/arousal support alongside other hormone protocols.
Side Effects & Safety
Nausea (~40%, most common), flushing, headache, transient blood pressure increase. Not studied in men in FDA trials — off-label male dosing is extrapolated from the approved female regimen.
Regulatory Status
FDA-ApprovedFDA-approved (Vyleesi, 2019) for acquired generalized hypoactive sexual desire disorder in premenopausal women. Use in men or other indications is off-label/research.
Evidence & Citations
Frequently asked
What is PT-141?+
PT-141 (Bremelanotide (Vyleesi)) is a peptide studied for melanocortin agonist and on-demand libido support. Melanocortin 3/4 receptor (MC3R/MC4R) agonist. Acts centrally on hypothalamic and mesolimbic circuits involved in sexual arousal, rather than on penile/vascular smooth muscle like PDE5 inhibitors — explaining its efficacy independent of vascular blood flow.
What is the dosing protocol for PT-141?+
Literature commonly references 1 mg PRN (low) to 1.75 mg PRN (maintenance) via SubQ (FDA-approved autoinjector); intranasal used in earlier trials, on a ongoing / prn cycle. Educational reference only — a licensed Stackhaus Health provider sets any personalized protocol.
What is the regulatory status of PT-141?+
FDA-approved (Vyleesi, 2019) for acquired generalized hypoactive sexual desire disorder in premenopausal women. Use in men or other indications is off-label/research.
Where can I access PT-141?+
Research-grade PT-141 is available through Stackhaus Research. For a personalized, provider-reviewed protocol, consult a licensed clinician through Stackhaus Health.
More in Muscle & Performance
Used in these stacks
PT-141 appears in 1 research protocol in the Stackhaus Academy library.